SIROLIMUS AZATHIOPRINE WITH IMMUNOSUPPRESSIVE THERAPY IN ALLOGRAFT RECIPIENTS

西罗莫司硫唑嘌呤与同种异体移植受者的免疫抑制治疗

• 批准号: 6274765
• 负责人: ALAN B LEICHTMAN
• 金额: $ 2.15万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274765
• 关键词: artificial immunosuppression; azathioprine; clinical research; combination chemotherapy; dosage; drug screening /evaluation; homologous transplantation; human subject; human therapy evaluation; kidney transplantation; sirolimus

To compare the safety and efficacy of two doses of sirolimus versus azathioprine, administered concomitantly with standard immunosuppressive therapy, on the combined endpoint of acute refection episodes, graft loss of death at six months post-transplant, in patients receiving renal allografts.

比较两种剂量西罗莫司与西罗莫司的安全性和有效性 硫唑嘌呤，与标准免疫抑制药同时使用 在急性反射发作的联合终点上进行治疗，移植 接受肾脏移植的患者在移植后6个月的死亡损失 异体移植。